5,6-dibromo-2-chloro-1H-benzimidazole | 142356-67-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 5,6-dibromo-2-chloro-1H-benzimidazole
• 英文别名: 2-chloro-5,6-dibromobenzimidazole；5,6-Dibromo-2-chloro-1H-1,3-benzodiazole
• CAS: 142356-67-0
• 化学式: C₇H₃Br₂ClN₂
• 分子量: 310.375
• InChiKey: ZKYRZYZWRSJKNP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  5,6-dibromo-2-chloro-1H-benzimidazole 在 一水合肼 作用下， 以 甲苯 、 乙腈 为溶剂， 反应 6.0h， 生成 ethyl 1-(5,6-dibromo-1H-benzimidazol-2-yl)-5-(2,3,4,5-tetrafluorophenyl)pyrazole-4-carboxylate
  参考文献：
  名称：

  Lipunova; Mokrushina; Nosova, Russian Journal of Organic Chemistry, 1997, vol. 33, # 10, p. 1476 - 1486

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氯苯并咪唑 在 溴 作用下， 以 甲醇 为溶剂， 反应 6.0h， 以72%的产率得到5,6-dibromo-2-chloro-1H-benzimidazole
  参考文献：
  名称：

  苯并咪唑，吲唑，苯并噻唑和噻唑的磺酰胺衍生物的分子建模，合成，抗菌和细胞毒性评估

  摘要：

  合成了一系列带有磺酰胺键的杂环分子，并筛选了其抗菌活性。期间使用broath稀释法筛选抗菌，发现分子是高度活性（MIC值50-3.1微克/毫升）对不同的人类病原体，即B. cerus，金黄色葡萄球菌，大肠杆菌和铜绿假单胞菌，和最有效的抗大肠杆菌。在FIC测定过程中观察到了很大的协同作用，其中分子与参考药物氯霉素和磺胺甲恶唑一起使用。组合的MIC值–变化的测试化合物浓度和参比药物的½MIC或变化的参考药物浓度和参比化合物的½MIC降低到1/ 4或1 / 32的原始值，从而指示组合为4-32倍，比试验分子更有效。该分子还显示出对PBM，CEM和VERO细胞系的低细胞毒性。结果肯定地表明了使用组合方法开发铅系抗菌剂的情况。

  DOI：

  10.1016/j.bmc.2018.05.015

文献信息

• Polysubstituted benzimidazoles as antiviral agents
  申请人：The Regents of the University of Michigan

  公开号：US05360795A1

  公开（公告）日：1994-11-01

  This invention relates to novel polysubstituted benzimidazoles and compositions and their use in the treatment of viral infections. The polysubstituted benzimidazoles and compositions of the present invention exhibit antiviral properties against viruses of the herpes family, particularly human cytomegalovirus (HCMV) and herpes simplex viruses (HSV). Preferred polysubstituted benzimidazoles of the invention are 2,5,6-Trichloro-1-(.beta.-D-5-deoxyribofuranosyl)benzimidazole and 2-bromo-5,6-dichloro-1-(5-deoxy-.beta.-D-ribofuranosyl)benzimidazole.

  这项发明涉及新型多取代苯并咪唑及其组合物，以及它们在治疗病毒感染中的用途。本发明的多取代苯并咪唑和组合物对疱疹病毒家族的病毒，特别是人类巨细胞病毒（HCMV）和单纯疱疹病毒（HSV）表现出抗病毒特性。该发明的首选多取代苯并咪唑是2,5,6-三氯-1-(β-D-5-脱氧核糖呋喃糖基)苯并咪唑和2-溴-5,6-二氯-1-(5-脱氧-β-D-核糖呋喃糖基)苯并咪唑。
• Treatment of herpes infections with polysubstituted benzimidazoles
  申请人：The Regents of the University of Michigan

  公开号：US05712255A1

  公开（公告）日：1998-01-27

  A method for treating a herpes viral infection comprising administering to the infected host a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or formulation thereof, selected from the group consisting of compounds having the following formula: ##STR1## wherein: R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Br and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 52 in the text); R.sub.1 is H, R.sub.2 is NO.sub.2, R.sub.3 is NO.sub.2, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 61 in the text); R.sub.1 is Cl, R.sub.2 is H, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 81 in the text); R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is I and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 83a in the text); R.sub.1 is Br, R.sub.2 is Br, R.sub.3 is H, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 85 in the text); R.sub.1 is H, R.sub.2 is Br, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 95 in the text); R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Br, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 99 in the text); R.sub.1 is H, R.sub.2 is I, R.sub.3 is I, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 107 in the text); R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is 2'-deoxy-.beta.-D-erythro-pentofuranosyl (denoted compound 111 in the text); R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Br and R.sub.6 is 2'-deoxy-.beta.-D-erythro-pentofuranosyl (denoted compound 112 in the text); R.sub.1 is Cl, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is Cl, R.sub.5 is Cl and R.sub.6 is (1,3-dihydroxy-2-propoxy)methyl (denoted compound 155 in the text); R.sub.1 is Cl, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is Cl, R.sub.5 is NH.sub.2 and R.sub.6 is (1,3-dihydroxy-2-propoxy)methyl (denoted compound 156 in the text); R.sub.1 is Cl, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is Cl, R.sub.5 is OCH.sub.3 and R.sub.6 is 2-hydroxyethoxymethyl (denoted compound 166a in the text); R.sub.1 is Cl, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is Cl, R.sub.5 is NH.sub.2 and R.sub.6 is 2-hydroxyethoxymethyl (denoted compound 167 in the text); and R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is NH.sub.2 and R.sub.6 is benzyl (denoted compound 182 in the text).

  一种治疗单纯疱疹病毒感染的方法，包括向受感染宿主投与以下化合物中的一种，或其在药学上可接受的盐或制剂，所述化合物具有以下公式： ##STR1## 其中：R.sub.1为H，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为H，R.sub.5为Br，R.sub.6为β-D-核糖呋喃（在文本中标记为化合物52）；R.sub.1为H，R.sub.2为NO.sub.2，R.sub.3为NO.sub.2，R.sub.4为H，R.sub.5为Cl，R.sub.6为β-D-核糖呋喃（在文本中标记为化合物61）；R.sub.1为Cl，R.sub.2为H，R.sub.3为Cl，R.sub.4为H，R.sub.5为Cl，R.sub.6为β-D-核糖呋喃（在文本中标记为化合物81）；R.sub.1为H，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为H，R.sub.5为I，R.sub.6为β-D-核糖呋喃（在文本中标记为化合物83a）；R.sub.1为Br，R.sub.2为Br，R.sub.3为H，R.sub.4为H，R.sub.5为Cl，R.sub.6为β-D-核糖呋喃（在文本中标记为化合物85）；R.sub.1为H，R.sub.2为Br，R.sub.3为Cl，R.sub.4为H，R.sub.5为Cl，R.sub.6为β-D-核糖呋喃（在文本中标记为化合物95）；R.sub.1为H，R.sub.2为Cl，R.sub.3为Br，R.sub.4为H，R.sub.5为Cl，R.sub.6为β-D-核糖呋喃（在文本中标记为化合物99）；R.sub.1为H，R.sub.2为I，R.sub.3为I，R.sub.4为H，R.sub.5为Cl，R.sub.6为β-D-核糖呋喃（在文本中标记为化合物107）；R.sub.1为H，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为H，R.sub.5为Cl，R.sub.6为2'-脱氧-β-D-erythro-戊呋喃核苷（在文本中标记为化合物111）；R.sub.1为H，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为H，R.sub.5为Br，R.sub.6为2'-脱氧-β-D-erythro-戊呋喃核苷（在文本中标记为化合物112）；R.sub.1为Cl，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为Cl，R.sub.5为Cl，R.sub.6为（1,3-二羟基-2-丙氧基）甲基（在文本中标记为化合物155）；R.sub.1为Cl，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为Cl，R.sub.5为NH.sub.2，R.sub.6为（1,3-二羟基-2-丙氧基）甲基（在文本中标记为化合物156）；R.sub.1为Cl，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为Cl，R.sub.5为OCH.sub.3，R.sub.6为2-羟基乙氧基甲基（在文本中标记为化合物166a）；R.sub.1为Cl，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为Cl，R.sub.5为NH.sub.2，R.sub.6为2-羟基乙氧基甲基（在文本中标记为化合物167）；R.sub.1为H，R.sub.2为Cl，R.sub.3为Cl，R.sub.4为H，R.sub.5为NH.sub.2，R.sub.6为苄基（在文本中标记为化合物182）。
• Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer
  作者：Jianyu Xu、Hongyun Qi、Zhen Wang、Ling Wang、Barbara Steurer、Xin Cai、Jinxin Liu、Alex Aliper、Man Zhang、Feng Ren、Alex Zhavoronkov、Xiao Ding

  DOI：10.1021/acs.jmedchem.4c00248

  日期：2024.5.23

  This molecule demonstrated not only decent enzymatic and cellular activities but also remarkable selectivity in CDK and kinome panels. Besides, compound 12 also displayed favorable ADME profiles including low CYP1A2 inhibition, acceptable clearance, and high oral bioavailability in multiple preclinical species. Robust in vivo PD and efficacy studies in mice models further demonstrated its potential

  介质激酶 CDK8 和 CDK19 响应各种信号控制选定基因的动态转录，并已被证明被各种实体和液体肿瘤劫持以维持过度增殖。 CDK8/19 正在成为一个有前景的抗癌治疗靶点。在这里，我们报告了化合物12的发现，这是一种新型小分子 CDK8/19 抑制剂。该分子不仅表现出良好的酶和细胞活性，而且在 CDK 和激酶组组中表现出显着的选择性。此外，化合物12还表现出良好的 ADME 特性，包括低 CYP1A2 抑制、可接受的清除率以及在多个临床前物种中的高口服生物利用度。小鼠模型中稳健的体内 PD 和疗效研究进一步证明了其作为治疗癌症的单一疗法和联合疗法的潜在用途。
• Design, Synthesis, and Antiviral Evaluation of 2-Chloro-5,6-dihalo-1-β-<scp>d</scp>-ribofuranosylbenzimidazoles as Potential Agents for Human Cytomegalovirus Infections
  作者：Ruiming Zou、John C. Drach、Leroy B. Townsend

  DOI：10.1021/jm960462g

  日期：1997.2.1

  2-Chloro-5,6-difluorobenzimidazole (8) was prepared from 4,5-difluoro-2-nitroaniline (5) via successive reduction, cyclization, and diazotization reactions. 2-Chloro-5,6-dibromobenzimidazole (10) was obtained by a direct bromination of 2-chlorobenzimidazole (9) with bromine-water. 2-Chloro-5,6-diiodobenzimidazole (15) was synthesized by a stepwise transformation of the nitro functions of 2-chloro-5,6-dinitrobenzimidazole (11) into iodo groups via diazotization reactions. Ribosylation of 8, 10, and 15 gave the respective beta nucleosides 16a-c as the major products along with a small amount of the alpha anomers 17a-c. Deprotection of 16a-c afforded the corresponding free beta nucleo sides 2-chloro-5,6-difluoro-1-beta-D-ribofuranosylbenzimidazole (2), 2-chloro-5,D-dibromo-1-beta-D-ribofuranosylbenzimidazole (3), and 2-chloro-5,6-diiodo-1-beta-D-ribofuranosylbenzimidazole (4). Similar deprotection of the alpha anomers (17a-c) resulted in a removal of the acetyl protecting groups and a concomitant cyclization to give the 2,2'-O-cyclonucleosides (18a-c). Most of the benzimidazole heterocycles, but not the difluoro analog, were active against human cytomegalovirus (HCMV) (IC50's = 3-40 mu M) and herpes simplex virus type 1 (HSV-1) (IC50's = 50-90 mu M). This activity, however, was not well separated from cytotoxicity, IC50's = 10-100 mu M. The corresponding unsubstituted, the 5,6-dimethyl, and the 5,6-difluoro ribonucleosides (19, 20, and 2, respectively), were inactive against both viruses. Similar to the previously reported 2,5,6-trichloro analog (TCRB), the 5,6-dibromo ribonucleoside 3 was active against HCMV (IC50 approximate to 4 mu M) but more cytotoxic than TCRB. The 5,6-diiodo analog 4 also was active (IC50 approximate to 2 mu M) but more cytotoxic (IC50 = 10-20 mu M) than either 3 or TCRB. The cyclonucleosides were inactive against both viruses and not cytotoxic, or slightly active with corresponding cytotoxicity. The order of activity against HCMV of the dihalobenzimidazole ribonucleosides was I similar or equal to Br similar or equal to Cl much greater than F > H = CH3. The order of cytotoxicity among the most active compounds, however, was I > Br > Cl, thereby establishing that TCRB had the best antiviral properties.
• POLYSUBSTITUTED BENZIMIDAZOLES AS ANTIVIRAL AGENTS
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：EP0556334A1

  公开（公告）日：1993-08-25